New Drug Controller of India (DCGI) takes over

New Delhi: Dr Eshwar Reddy is the new Drug Controller of India (DCGI). He takes over the charge from Dr G.N. Singh.

Dr Reddy bucks the trend in the sense that he is not a political appointee. He is from within the department and is seized of a well thought out Pharma vision 2030.  Perhaps After a long time, he is a professional appointee as in the past most DCGI were political nominations from outside department. For long term Pharma vision, he is considered the most eligible one for this post.

Dr Reddy has leadership qualities and it is hugely hoped that he would come out with flying colours during his three month probation. Medical device sector has been his pet subject.

Rajiv Nath, Forum Coordinator, Association of Indian Medical device industry (AiMeD), has expressed utmost pleasure on his appointment and not being a political appointee. Dr Reddy was joint drug controller of India.

  • Related Posts

    WHO launches new primary health care course to strengthen health systems globally

    Health is a human right – yet not everyone can access the health services they need, when and where they need them, without financial hardship. Primary health care (PHC) provides…

    Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

    Bengaluru: The Central Council for Research in Ayurvedic Sciences (CCRAS) has called for stronger scientific evidence, safety monitoring and translation of research into market-ready technologies to improve the credibility and…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    WHO launches new primary health care course to strengthen health systems globally

    WHO launches new primary health care course to strengthen health systems globally

    Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

    Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert